|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||||
| Cash and due from banks | |||||||||||||||||||
| Money market funds | |||||||||||||||||||
| Federal funds sold | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Interest-bearing time deposits with other banks | |||||||||||||||||||
| Available-for-sale securities, at fair value | |||||||||||||||||||
| Equity securities, at fair value | |||||||||||||||||||
| Total Investments | |||||||||||||||||||
| Federal Home Loan Bank stock, at cost | |||||||||||||||||||
| Loans, net of allowance for loan losses of $1,354 at March 31, 2019 and $1,323 at December 31, 2018 | |||||||||||||||||||
| Premises and equipment, net | |||||||||||||||||||
| Co-operative Central Bank deposit | |||||||||||||||||||
| Bank-owned life insurance | |||||||||||||||||||
| Accrued interest receivable | |||||||||||||||||||
| Deferred tax asset, net | |||||||||||||||||||
| Other assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||||||||||
| Deposits: | |||||||||||||||||||
| Noninterest-bearing | |||||||||||||||||||
| Interest-bearing | |||||||||||||||||||
| Total deposits | |||||||||||||||||||
| Deferred tax liability, net | |||||||||||||||||||
| Federal Home Loan Bank advances | |||||||||||||||||||
| Other liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| Stockholders' equity: | |||||||||||||||||||
| Common stock, par value $0.01 per share, authorized 15,000,000 shares; issued and outstanding 2,440,133 shares at March 31, 2019 and 2,573,024 shares at December 31, 2018 | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Retained earnings | |||||||||||||||||||
| Unearned compensation - ESOP (186,752 shares unallocated at March 31, 2019 and 188,638 shares unallocated at December 31, 2018) | |||||||||||||||||||
| Unearned compensation - restricted stock | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Total stockholders' equity | |||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...
